|Bid||3.8200 x 900|
|Ask||3.8600 x 4000|
|Day's Range||3.8100 - 4.3000|
|52 Week Range||2.5800 - 136.0000|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ADTX
Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
RICHMOND, Va., September 29, 2022--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel ("Nasdaq") that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), meets the stockholders’ equity requirement
RICHMOND, Va., September 27, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today provides shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering.